Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
SPRO Price/Volume Stats
| Current price | $2.56 | 52-week high | $2.95 |
| Prev. close | $2.66 | 52-week low | $0.51 |
| Day low | $2.52 | Volume | 1,771,900 |
| Day high | $2.69 | Avg. volume | 2,308,150 |
| 50-day MA | $0.93 | Dividend yield | N/A |
| 200-day MA | $1.05 | Market Cap | 143.13M |
SPRO Stock Price Chart Interactive Chart >
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
SPRO Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SPRO Price Returns
| 1-mo | 342.91% |
| 3-mo | 228.63% |
| 6-mo | 118.80% |
| 1-year | 76.55% |
| 3-year | 104.80% |
| 5-year | -79.42% |
| YTD | 148.54% |
| 2024 | -29.93% |
| 2023 | -15.03% |
| 2022 | -89.19% |
| 2021 | -17.43% |
| 2020 | 101.66% |